Search Results - "David, Porter"

Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies by Freyer, Craig W., Porter, David L.

“…Chimeric antigen receptor T cells are a new and exciting immunotherapeutic approach to managing cancer, with impressive efficacy but potentially…”
Get full text

CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia by Maude, Shannon L., Teachey, David T., Porter, David L., Grupp, Stephan A.

“…Relapsed and refractory acute lymphoblastic leukemia (ALL) remains difficult to treat, with minimal improvement in outcomes seen in more than 2 decades despite…”
Get full text

Current concepts in the diagnosis and management of cytokine release syndrome by Lee, Daniel W., Gardner, Rebecca, Porter, David L., Louis, Chrystal U., Ahmed, Nabil, Jensen, Michael, Grupp, Stephan A., Mackall, Crystal L.

“…As immune-based therapies for cancer become potent, more effective, and more widely available, optimal management of their unique toxicities becomes…”
Get full text

Fifth Metatarsal Jones Fractures in the Athlete by Porter, David A.

“…Fifth metatarsal fractures, otherwise known as “Jones” fractures, occur commonly in athletes and nonathletes alike. While recent occurrence in the popular…”
Get full text

High resolution diffusion-weighted imaging using readout-segmented echo-planar imaging, parallel imaging and a two-dimensional navigator-based reacquisition by Porter, David A., Heidemann, Robin M.

“…Single‐shot echo‐planar imaging (EPI) is well established as the method of choice for clinical, diffusion‐weighted imaging with MRI because of its low…”
Get full text

Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia by Frey, Noelle V, Porter, David L

“…T-cell-engaging immunotherapies are exciting new approaches to treat patients with acute lymphoblastic leukemia (ALL). These unique agents, which include…”
Get full text

Chimeric antigen receptor T cell therapy: 25 years in the making by Gill, Saar, Maus, Marcela V, Porter, David L

“…Abstract Chimeric antigen receptor (CAR) T cell therapy of cancer is generating enormous enthusiasm. Twenty-five years after the concept was first proposed,…”
Get full text

VORTICITY, SHOCKS, AND MAGNETIC FIELDS IN SUBSONIC, ICM-LIKE TURBULENCE by Porter, David H., Jones, T. W., Ryu, Dongsu

“…ABSTRACT We analyze data from high resolution simulations of the generation of compressible, MHD turbulence with properties chosen to resemble conditions in…”
Get full text

What Makes a Good Trader? On the Role of Intuition and Reflection on Trader Performance by CORGNET, BRICE, DESANTIS, MARK, PORTER, DAVID

“…Using laboratory experiments, we provide evidence on three factors influencing trader performance: fluid intelligence, cognitive reflection, and theory of mind…”
Get full text

Antibody-modified T cells: CARs take the front seat for hematologic malignancies by Maus, Marcela V., Grupp, Stephan A., Porter, David L., June, Carl H.

“…T cells redirected to specific antigen targets with engineered chimeric antigen receptors (CARs) are emerging as powerful therapies in hematologic…”
Get full text

Silk as a Biomimetic Ideal for Structural Polymers by Porter, David, Vollrath, Fritz

“…Two factors are critical for understanding silks: the nanoscale semicrystalline folding structure, which gives high strength and toughness, and the degree of…”
Get full text

Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia by Porter, David L, Levine, Bruce L, Kalos, Michael, Bagg, Adam, June, Carl H

“…A patient with refractory CLL had delayed development of the rapid tumor lysis syndrome and remission after an infusion of T cells engineered to express an…”
Get full text

Chimeric Antigen Receptor Therapy for Cancer by Barrett, David M, Singh, Nathan, Porter, David L, Grupp, Stephan A, June, Carl H

“…Improved outcomes for patients with cancer hinge on the development of new targeted therapies with acceptable short-term and long-term toxicity. Progress in…”
Get full text

Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas by Schuster, Stephen J, Svoboda, Jakub, Chong, Elise A, Nasta, Sunita D, Mato, Anthony R, Anak, Özlem, Brogdon, Jennifer L, Pruteanu-Malinici, Iulian, Bhoj, Vijay, Landsburg, Daniel, Wasik, Mariusz, Levine, Bruce L, Lacey, Simon F, Melenhorst, Jan J, Porter, David L, June, Carl H

“…Among 38 patients with refractory diffuse large B-cell lymphoma or follicular lymphoma, 28 were able to receive CAR T cells; 16 had complete remission, and…”
Get full text

Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia by Mueller, Karen Thudium, Maude, Shannon L., Porter, David L., Frey, Noelle, Wood, Patricia, Han, Xia, Waldron, Edward, Chakraborty, Abhijit, Awasthi, Rakesh, Levine, Bruce L., Melenhorst, J. Joseph, Grupp, Stephan A., June, Carl H., Lacey, Simon F.

“…Tisagenlecleucel (CTL019) is an investigational immunotherapy that involves reprogramming a patient's own T cells with a transgene encoding a chimeric antigen…”
Get full text

Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes by Scott, Bart L, Pasquini, Marcelo C, Logan, Brent R, Wu, Juan, Devine, Steven M, Porter, David L, Maziarz, Richard T, Warlick, Erica D, Fernandez, Hugo F, Alyea, Edwin P, Hamadani, Mehdi, Bashey, Asad, Giralt, Sergio, Geller, Nancy L, Leifer, Eric, Le-Rademacher, Jennifer, Mendizabal, Adam M, Horowitz, Mary M, Deeg, H Joachim, Horwitz, Mitchell E

“…Purpose The optimal regimen intensity before allogeneic hematopoietic cell transplantation (HCT) is unknown. We hypothesized that lower treatment-related…”
Get full text

Glossing Abbo with Ælfric’s Grammar/Glossary by Porter, David W.

“…The essay identifies the Grammar/Glossary of the homilist Ælfric as the source for the continuous Old English gloss to the prose version of Abbo of St…”
Get full text

Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies by Ruella, Marco, Barrett, David M, Kenderian, Saad S, Shestova, Olga, Hofmann, Ted J, Perazzelli, Jessica, Klichinsky, Michael, Aikawa, Vania, Nazimuddin, Farzana, Kozlowski, Miroslaw, Scholler, John, Lacey, Simon F, Melenhorst, Jan J, Morrissette, Jennifer J D, Christian, David A, Hunter, Christopher A, Kalos, Michael, Porter, David L, June, Carl H, Grupp, Stephan A, Gill, Saar

“…Potent CD19-directed immunotherapies, such as chimeric antigen receptor T cells (CART) and blinatumomab, have drastically changed the outcome of patients with…”
Get full text

Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor–modified T cells by Gill, Saar, Tasian, Sarah K., Ruella, Marco, Shestova, Olga, Li, Yong, Porter, David L., Carroll, Martin, Danet-Desnoyers, Gwenn, Scholler, John, Grupp, Stephan A., June, Carl H., Kalos, Michael

“…Many patients with acute myeloid leukemia (AML) are incurable with chemotherapy and may benefit from novel approaches. One such approach involves the transfer…”
Get full text

Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel by Porter, David, Frey, Noelle, Wood, Patricia A, Weng, Yanqiu, Grupp, Stephan A

“…Anti-CD19 CAR T cell therapy has demonstrated high response rates in patients with relapsed or refractory (r/r) B cell malignancies but is associated with…”
Get full text